| Mon, Dec 7, 2009 | | • | AS1413 regimen yields high response rate and durable responses in patients with secondary AML, a poor-risk population underserved by current treatment options
Marketwire (Mon, Dec 7)
| | Tue, Nov 10, 2009 | | • | Antisoma AGM update and Interim Management Statement
Marketwire (Tue, Nov 10)
| | Tue, Oct 13, 2009 | | • | Antisoma's AS1411 gains US and EU Orphan Drug Status for acute myeloid leukaemia
Marketwire (Tue, Oct 13)
| | Fri, Oct 9, 2009 | | • | Annual Report and Accounts 2009
Marketwire (Fri, Oct 9)
| | Thu, Oct 8, 2009 | | • | Antisoma to amend ACCEDE phase III study of AS1413
Marketwire (Thu, Oct 8)
| | Fri, Sep 18, 2009 | | • | Antisoma to present at the UBS Global Life Sciences Conference in New York
Marketwire (Fri, Sep 18)
| | Wed, Sep 16, 2009 | | • | Antisoma to present at the Bank of America Merrill Lynch Global Healthcare Conference in London
Marketwire (Wed, Sep 16)
| | Mon, Sep 14, 2009 | | • | Antisoma's preliminary results for the year ended 30 June 2009
Marketwire (Mon, Sep 14)
| | Thu, Sep 3, 2009 | | • | Antisoma to present at the Rodman & Renshaw Healthcare Conference in New York
Marketwire (Thu, Sep 3)
| | Tue, Sep 1, 2009 | | • | Phase III trial of ASA404 in lung cancer completes patient enrolment
Marketwire (Tue, Sep 1)
| | Tue, Aug 11, 2009 | | • | Antisoma and Bryan Oncor announce deal for anti-cancer drug P2045
Marketwire (Tue, Aug 11)
| | Fri, Aug 7, 2009 | | • | Antisoma announces discontinuation of development of AS1402
Marketwire (Fri, Aug 7)
| | Wed, Aug 5, 2009 | | • | Antisoma to present at the Canaccord Adams 29th Annual Global Growth Conference in Boston
Marketwire (Wed, Aug 5)
| | Thu, Jun 18, 2009 | | • | Antisoma to present at Piper Jaffray Europe Conference in London
Marketwire (Thu, Jun 18)
| | Mon, Jun 15, 2009 | | • | Antisoma to present at 3rd Annual Jefferies Healthcare Conference in New York
Marketwire (Mon, Jun 15)
| | Fri, Jun 5, 2009 | | • | Antisoma to present at 8th Annual Needham Life Sciences Conference in New York
Marketwire (Fri, Jun 5)
| | Sun, May 31, 2009 | | • | Antisoma's AS1409 shows anti-cancer activity in phase I trial
Marketwire (Sun, May 31)
| | Fri, May 29, 2009 | | • | Antisoma to advance AS1411 in AML based on positive phase II data presented at ASCO
Marketwire (Fri, May 29)
| | Thu, May 21, 2009 | | • | Phase II trial of ASA404 published in Lung Cancer
Marketwire (Thu, May 21)
| | Tue, May 12, 2009 | | • | Antisoma sells oral fludarabine to sanofi-aventis U.S. for USD 65 million
Marketwire (Tue, May 12)
|
Add AIOAF.PK News to My Yahoo!:
 
| |
|
0.83% Nasdaq 
Headlines
